Sign In
Buy BIAF
$1.69
+0.0100 (+0.595%)
At Close: Jun 03, 2026
bioAffinity Technologies Reports First Quarter 2025 Results
08:30am, Thursday, 15'th May 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports first-quarter 2025 results.
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering
01:15pm, Wednesday, 07'th May 2025
JERSEY CITY, N.J. , May 7, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc.
bioAffinity Technologies Announces Closing of $3.25 Million Offering
01:00pm, Wednesday, 07'th May 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today closed the previously announced best efforts offering of securities for aggregate gross proceeds of $3.25 million.
bioAffinity Technologies Announces Pricing of $3.25 Million Offering
09:25am, Tuesday, 06'th May 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces the pricing of a best efforts offering of securities for aggregate gross proceeds of $3.25 million.
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost
09:15am, Thursday, 17'th Apr 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies is implementing efficiency measures for CyPath Lung that streamline lab processing and data acquisition and reduce lab costs.
BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues
01:20pm, Monday, 07'th Apr 2025
bioAffinity witnesses record 2024 revenues, driven by CyPath Lung adoption, Medicare coverage and strategic expansion across healthcare networks.
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
09:28am, Monday, 31'st Mar 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies, Inc. (BIAF) releases financial results for 2024.
Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer
09:00am, Wednesday, 26'th Mar 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies' CyPath Lung test uncovered a hidden second primary lung cancer in a patient who had been treated for lung cancer earlier.
Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence
09:00am, Wednesday, 19'th Mar 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--In another case study, CyPath® Lung helped physicians identify and treat a recurrence of breast cancer in a high-risk patient.
bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth
08:00am, Thursday, 06'th Mar 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today announced strategic actions to cut $4 million in annual costs at its subsidiary CAP/CLIA pathology laboratory.
bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
11:30am, Wednesday, 26'th Feb 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of warrant inducement transaction for aggregate gross proceeds of $1.4 million.
WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
11:05am, Tuesday, 25'th Feb 2025
JERSEY CITY, N.J. , Feb. 25, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, In
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
09:58am, Tuesday, 25'th Feb 2025
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity has entered into warrant exercise agreements to exercise certain outstanding warrants for gross cash proceeds of $1.4 million.
Zacks Initiates Coverage of bioAffinity With Neutral Recommendation
11:40am, Thursday, 06'th Feb 2025
Discover why Zacks rates bioAffinity as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore BIAF's promising growth prospects and financial health amid market challeng
ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small S
